title: Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.
abstract: Novel treatments for gastrointestinal (GI) diseases are based on molecular targets. Novel pharmacologic and biological agents with greater selectivity and specificity are being developed for a variety of epithelial diseases, including eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), celiac disease, short bowel syndrome (SBS), and inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis). Motility and secretory agents are being developed for gastroparesis, irritable bowel syndrome (IBS), functional constipation, and diarrhea. Here we focus on data from clinical trials involving validated pharmacodynamic or patient response outcomes.
authors: Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors: D A
authors: DA
authors: Katzka
authors: E V
authors: EV
authors: Loftus
authors: M
authors: M
authors: Camilleri
mesh_terms: D002446:Celiac Disease / Q000188:drug therapy; D057765:Eosinophilic Esophagitis / Q000188:drug therapy; D004942:Esophagitis, Peptic / Q000188:drug therapy; D005758:Gastritis, Hypertrophic / Q000188:drug therapy; D005765:Gastrointestinal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D005769:Gastrointestinal Motility / Q000187:drug effects; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D041981:Gastrointestinal Tract / Q000187:drug effects; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D018664:Interleukin-12 / Q000037:antagonists & inhibitors; D053759:Interleukin-23 / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D005765:Gastrointestinal Agents; D053759:Interleukin-23; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12